Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
Information source: M.D. Anderson Cancer Center
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Leukemia, Myeloid; Myelodysplastic Syndromes
Intervention: Gleevec (Drug); Ara-C (Drug)
Phase: Phase 2
Sponsored by: M.D. Anderson Cancer Center
Official(s) and/or principal investigator(s):
Jorge E Cortes, MD, Principal Investigator, Affiliation: The University of M.D. Anderson Cancer Center
The goal of this clinical research study is to learn if the combination of Gleevec (imatinib
mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing
fewer side effects than standard high dose chemotherapy.
Official title: Phase II Trial of Gleevec and Low-Dose Ara-C for Elderly Patients With C-Kit Positive Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: To determine the efficacy of a combination of imatinib and low dose ara-C in elderly or high-risk patients with AML and MDS, as measured by the rate of early mortality or progression.
To determine the rate of overall response, including CRp and PR.
To determine the safety profile of this combination.
To determine the impact on long-term survival of this therapy.
To determine the duration of responses obtained with this therapy.
To determine the impact of this therapy in cognitive function.
To determine the effect of this approach in quality of life of this patient population.
To determine the overall costs (health economic analysis) associated with this combination therapy.
Imatinib mesylate is a drug that blocks a certain protein. This protein is thought to be
important in the growth of leukemia cells. Ara-C is a chemotherapy drug that has been used
for many years to treat AML and MDS.
Imatinib mesylate (Gleevec) is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl
tyrosine kinase, as well as the receptor tyrosine kinases for platelet- derived growth factor
(PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular
events. c-Kit is expressed in over 90% of patients with AML.
The treatment of AML for patients age 65 or older with AML or high-risk MDS (age ³ 60 if
high-risk cytogenetics) have a poor prognosis with induction chemotherapy. Response rate is
no more than 45% with an induction mortality of at least 25%, and 1-year survival no better
than 20%. Indeed, most patients in these age groups are not even offered therapy and are
managed with supportive care only. Thus, new therapies that are better tolerated are
Imatinib alone can induce response in nearly 20% of patients, and there is synergy with low
concentrations of ara-C. In this study we plan to investigate the combination of imatinib
and low-dose ara-C.
Minimum age: 60 Years.
Maximum age: N/A.
- Patients who are not candidates for intensive chemotherapy with any of the following
diagnosis: 1. AML or MDS (with >/=5% blasts) age >/= 65 years old (or age >/= 60 if
high-risk cytogenetics), or 2. AML or MDS (RAEB or RAEBT) of any cytogenetic group age
60 or older with minimally treated disease who have relapsed disease or are refractory
to therapy and not likely to require cytoreductive therapy within one month, and, or
- Patients with WHO performance status of 0 to 2
- Patients must have recovered from prior cytotoxic chemotherapy; treatment with hydrea
is allowed up to 24 hours prior to day 1 of study drug administration
- Written informed consent obtained according to local guidelines
- Patients must have a serum creatinine of = 1. 5 x ULN, SGPT = 3 x ULN and total
bilirubin = 2. 0 x ULN.
- Patients with >/= 20% blasts positive for c-kit (CD117) (except for CMML)
- Postmenopausal women must be amenorrheic for at least 12 months to be considered of
non-childbearing potential. Male and female patients of childbearing potential must
agree to employ an effective method of birth control throughout the study and for up
to 3 months following discontinuation of study drug.
- Patients with uncontrolled active infection
- Patients with NYHA class III or IV
- Women who are pregnant
- Women who are breast feeding
Locations and Contacts
The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, United States
M.D. Anderson's website
Starting date: March 2004
Last updated: May 21, 2007